GLP-1 Compounding Just Got More Complicated: 7 Steps to Keep Your Med Spa Compliant

GLP-1 treatments remain a major part of many med spa and wellness clinic programs. They can support patients managing weight and metabolic health: but the rules around compounded semaglutide and tirzepatide have become much stricter.

In 2026, the FDA is focusing on mass-marketed compounded GLP-1 products, misleading advertising, questionable sourcing, dosing errors, and products that are presented as substitutes for FDA-approved medications. For med spa owners, this means the pharmacy relationship behind your program matters more than ever.

A reliable med spa pharmacy partner should do more than ship medication. Your partner should help your clinic maintain patient-specific prescribing, clear documentation, appropriate sourcing, safe handling, and accurate communication.

Below are seven practical steps to help your clinic review its GLP-1 program.

Important: This article is for general education and is not legal, regulatory, or medical advice. Requirements may vary by state and change over time. Work with qualified legal, medical, and pharmacy professionals before changing your program.

Why compounded GLP-1 programs are under greater scrutiny

The FDA states that compounded drugs are not FDA-approved. Unlike FDA-approved medications, they are not reviewed by the agency for safety, effectiveness, or quality before being marketed.

Compounding may be appropriate when a patient’s medical needs cannot be met by an FDA-approved product: for example, when a patient needs a formulation without a specific inactive ingredient or requires a dosage form that is not commercially available.

However, compounded medications should not be treated as generic versions of FDA-approved drugs. The FDA specifically says compounded drugs and generic drugs are not the same.

The agency has also warned companies against claiming that compounded GLP-1 products are:

• Generic versions of Wegovy, Ozempic, Mounjaro, or Zepbound
• The same as FDA-approved products
• Equivalent to FDA-approved products
• Made with “the same active ingredient” in a way that implies FDA approval or therapeutic equivalence
• Clinically proven to produce the same results as an FDA-approved medication

The FDA’s February 2026 statement on non-FDA-approved GLP-1 drugs outlines the agency’s concerns and potential enforcement tools.

7 steps to strengthen your med spa’s GLP-1 compliance

1. Confirm exactly who compounds and dispenses the medication

Start with the basics: identify the pharmacy or outsourcing facility behind every GLP-1 product your clinic uses.

Ask for:

• The pharmacy’s legal name and physical address
• State pharmacy licenses
• Whether the pharmacy operates under Section 503A or Section 503B
• The states where it is authorized to dispense
• The name and contact information of the responsible pharmacist
• A clear process for prescription questions and patient support

Your clinic should not rely on a vague private label or a website that hides the actual compounder. The FDA has warned about fraudulent compounded products carrying the names of pharmacies that did not make them: or, in some cases, pharmacies that do not exist.

A transparent wellness clinic pharmacy support partner should make this information easy to verify.

2. Use patient-specific prescriptions and document the clinical rationale

Under Section 503A, compounding is generally tied to an individual patient and a prescription from a licensed prescriber. A clinic should be able to connect every compounded medication to:

• A specific patient
• A valid prescription
• A documented evaluation
• A treatment plan
• A clinical reason for using a compounded formulation

The rationale should be more specific than “the patient prefers a lower price” or “the clinic uses this for all weight-loss patients.”

The FDA’s April 2026 guidance update explains that a compounded product may be considered an “essentially a copy” of a commercially available drug unless the prescriber documents a significant difference for an identified patient.

Your pharmacy partner can help standardize the information needed for each prescription, but the prescriber remains responsible for making appropriate clinical decisions and maintaining accurate records.

3. Review whether your program is relying on office stock

A common compliance question is whether your clinic is ordering compounded GLP-1 medication in bulk and keeping it as routine office stock.

Traditional 503A pharmacy compounding is patient-specific. That may not align with a program where a med spa purchases large quantities of compounded injections for general use among patients who qualify through a simple screening process.

Review:

• How medication is ordered
• Whether each order is linked to a named patient
• Whether doses are dispensed directly to the patient or supplied as general stock
• Whether your arrangement is actually appropriate for the pharmacy’s compounding category
• Whether your state has additional requirements for administration, storage, or dispensing

Do not assume that a high-volume model is automatically permitted because another clinic uses it. Ask your pharmacy and legal advisors to review the structure of your program.

4. Audit every marketing claim

Your website, social media, email campaigns, patient handouts, intake forms, and sales scripts should all use the same careful language.

Avoid statements such as:

• “Generic Ozempic”
• “The same as Wegovy”
• “Equivalent to Zepbound”
• “FDA-approved compounded semaglutide”
• “Clinically proven to work just like the brand”
• “Uses the same active ingredient as the FDA-approved drug”

Be cautious with before-and-after photos, guaranteed outcomes, rapid weight-loss promises, and pricing that makes a compounded product appear to be a direct substitute for an FDA-approved medication.

Instead, use factual language. For example:

“Our clinicians evaluate each patient individually and discuss FDA-approved and compounded treatment options when appropriate. Compounded medications are not FDA-approved and may be considered only when a patient’s medical needs cannot be met by an FDA-approved product.”

Have your medical director, compliance advisor, and pharmacy partner review the final language before publication.

5. Verify the ingredient source and formulation

Ingredient quality is a critical part of safe compounding. Ask your pharmacy how it verifies:

• Ingredient identity
• Strength and purity
• Supplier qualification
• Lot numbers and expiration dates
• Storage and handling requirements
• Testing and release procedures
• Whether the formulation uses an appropriate active ingredient

The FDA has specifically raised concerns about semaglutide salt forms, including semaglutide sodium and semaglutide acetate. The agency states that these are different active ingredients from the one used in approved products and that it is not aware of a lawful basis for their use in compounding.

Your clinic should also avoid products sold as “research use only” or “not for human consumption.” Those labels do not make a product appropriate for patient care.

6. Build a stronger dosing, education, and shipping process

Dosing errors have been a significant concern with compounded injectable semaglutide and tirzepatide. Confusion can occur when prescriptions use different concentrations, vial sizes, syringe markings, or units.

Your process should clearly explain:

• The prescribed dose
• The concentration of the medication
• The volume to draw into the syringe
• The injection schedule
• How and when titration occurs
• What to do after a missed dose
• How to store the medication
• Who to contact with questions

Use written instructions and, when appropriate, demonstrate administration during the patient visit. Make sure the prescription, pharmacy label, patient handout, and clinic instructions all match.

Shipping is another safety checkpoint. Injectable medications may require refrigeration. The FDA recommends that patients not use an injectable GLP-1 product that arrives warm or without adequate refrigeration. Establish a process for reporting shipping problems, replacing compromised medication, and documenting the incident.

7. Create an ongoing pharmacy-partner review

Compliance is not a one-time checklist. Your pharmacy partner, product sourcing, state requirements, and FDA expectations may change.

At least periodically, review:

• Pharmacy licenses and registration status
• Product labels and patient instructions
• Quality and testing documentation
• Shipping performance
• Complaint and adverse-event procedures
• Recall communication
• Marketing materials
• Regulatory updates and warning letters
• Turnaround times and prescription accuracy

This is where a responsive pharmacy relationship can make a real difference. WeCare RX supports healthcare providers, wellness clinics, and other clinical partners with pharmacy coordination and customized medication services. Our goal is to help practices build a clear process around prescription intake, patient-specific needs, medication questions, and ongoing communication.

If your clinic is evaluating compounded peptides for clinics, do not focus only on price or turnaround time. Ask whether the pharmacy can support the documentation, patient education, quality communication, and operational controls your program requires.

What to look for in a med spa pharmacy partner

A strong partner should be willing to answer direct questions and provide clear documentation. Look for a pharmacy that offers:

• Transparent licensing and pharmacy information
• A defined prescription process
• Patient-specific workflow support
• Clear labeling and dosing instructions
• Reliable cold-chain shipping procedures
• Pharmacist access for questions
• Quality-control information
• Adverse-event and complaint support
• Practical communication with your clinical team

No pharmacy can remove your clinic’s responsibility to prescribe and market appropriately. But the right partner can make it easier to identify gaps before they become patient-safety or compliance problems.

The bottom line

The safest path for med spas in 2026 is not a mass-market subscription model built around a compounded GLP-1 by default. It is a patient-centered program with careful prescribing, documented clinical reasoning, transparent sourcing, accurate marketing, and strong follow-up.

Review your program now. Audit the claims on your website. Confirm how every product is sourced and dispensed. Then choose a med spa pharmacy partner that is prepared to support your clinic with clear processes and reliable communication.

For additional background, review the FDA’s resources on compounded GLP-1 drugs used for weight loss and compounding requirements. When your clinic is ready to review its pharmacy workflow, WeCare RX can help you think through the operational support your providers and patients need.